Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu

Cancer Gene Therapy

Volumn 14, Issue 5, 2007, Pages 468-479

  Magnusson, M K ^a,b   Henning, P ^a,b   Myhre, S ^a,b   Wikman, M ^c   Uil, T G ^d   Friedman, M ^c   Andersson, K M E ^a,b   Hong, S S ^e   Hoeben, R C ^d   Habib, N A ^f   Stahl S ^c   Boulanger, P ^e   Lindholm, L ^a,b  

^a Got A Gene AB   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITÉ LYON 1   (France)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adenovirus; Affibody molecules; Fiber; HER2 neu; HI loop; Re targeting

Indexed keywords

ADENOVIRUS VECTOR; AFFIBODY; BINDING PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG SPECIFICITY; DRUG TARGETING; GENE INSERTION; GENE SEQUENCE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; TANDEM REPEAT;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; HUMAN ENTEROVIRUS B;

EID: 34247168525     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701027     Document Type: Article

References (55)

1. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573-2604.
2. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
3. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
4. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
5. Akiyama M, Thorne S, Kirn D, Roelvink PW, Einfeld DA, King CR et al. Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol Ther 2004; 9: 218-230.
6. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
7. Kirby I, Davison E, Beavil AJ, Soh CP, Wickham TJ, Roelvink PW et al. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol 1999; 73: 9508-9514.
8. Bewley MC, Springer K, Zhang YB, Freimuth P, Flanagan JM. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999; 286: 1579-1583.
9. Kirby I, Davison E, Beavil AJ, Soh CP, Wickham TJ, Roelvink PW et al. Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J Virol Mar 2000; 74: 2804-2813.
10. Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing 'de-knobbing' of the fiber. J Virol 2001; 75: 7280-7289.
11. Magnusson MK, Hong SS, Henning P, Boulanger P, Lindholm L. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 2002; 4: 356-370.
12. Henning P, Magnusson MK, Gunneriusson E, Hong SS, Boulanger P, Nygren PA et al. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from Staphylococcal protein A. Hum Gene Ther 2002; 13: 1427-1439.
13. van Beusechem VW, van Rijswijk AL, van Es HH, Haisma HJ, Pinedo HM, Gerritsen WR. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Therapy 2000; 7: 1940-1946.
14. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
15. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003; 14: 777-787.
16. Karayan L, Hong SS, Gay B, Tournier J, d'Angeac AD, Boulanger P. Structural and functional determinants in adenovirus type 2 penton base recombinant protein. J Virol 1997; 71: 8678-8689.
17. Curiel DT. Strategies to alter the tropism of adenoviral vectors via genetic capsid modifications. In: Curiel DT, Douglas JT (eds). Vector targeting for therapeutic gene delivery. Wiley-Liss Inc.: Hoboken, 2002, pp 171-200.
18. Nilsson B, Moks T, Jansson B, Abrahmsen L, Elmblad A, Holmgren E et al. A synthetic IgG-binding domain based on Staphylococcal protein A. Protein Eng 1987; 1: 107-113.
19. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997; 15: 772-777.
20. Legrand V, Spehner D, Schlesinger Y, Settelen N, Pavirani A, Mehtali M. Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. J Virol 1999; 73: 907-919.
21. Miyazawa N, Leopold PL, Hackett NR, Ferris B, Worgall S, Falck-Pedersen E et al. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol 1999; 73: 6056-6065.
22. Miyazawa N, Crystal RG, Leopold PL. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol 2001; 75: 1387-1400.
23. Shayakhmetov DM, Li ZY, Ternovoi V, Gaggar A, Gharwan H, Lieber A. The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J Virol 2003; 77: 3712-3723.
24. Gaden F, Franqueville L, Magnusson MK, Hong SS, Merten MD, Lindholm L et al. Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells. J Virol 2004; 78: 7227-7247.
25. Miyazawa N, Crystal RG, Leopold PL. Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol 2001; 75: 1387-1400.
26. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-1852.
27. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1Part 1: 391-405.
28. Fontana L, Nuzzo M, Urbanelli L, Monaci P. General strategy for broadening adenovirus tropism. J Virol Oct 2003; 77: 11094-11104.
29. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 1999; 59: 1196-1201.
30. Wikman M, Steffen AC, Gunneriusson E, Adams GP, Carlsson J, Stahl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004; 18: 18.
31. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578.
32. Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 2005; 20: 239-248.
33. Wang SC, Hung MC. HER2 overexpression and cancer targeting. Semin Oncol 2001; 28: 115-124.
34. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
35. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
36. Hong JS, Engler JA. Domains required for assembly of adenovirus type 2 fiber trimers. J Virol 1996; 70: 7071-7078.
37. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-4755.
38. Hansson M, Ringdahl J, Robert A, Power U, Goetsch L, Nguyen TN et al. An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 1999; 4: 237-252.
39. Hoppe HJ, Barlow PN, Reid KB. A parallel three stranded alpha-helical bundle at the nucleation site of collagen triple-helix formation. FEBS Lett 1994; 344: 191-195.
40. Henning P, Andersson KM, Frykholm K, Ali A, Magnusson MK, Nygren PA et al. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Therapy 2005; 12: 211-224.
41. O'Reilly DR, Miller LK, Luckow VA. Virus methods. In: Press OU (ed). Baculovirus Expression Vectors. A Laboratory Manual. Oxford University Press Inc: Oxford, England, 1994, pp 124-138.
42. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
43. Gaden F, Franqueville L, Hong SS, Legrand V, Figarella C, Boulanger P. Mechanism of restriction of normal and cystic fibrosis transmembrane conductance regulator-deficient human tracheal gland cells to adenovirus infection and ad-mediated gene transfer. Am J Respir Cell Mol Biol 2002; 27: 628-640.
44. Brinkmann U, Buchner J, Pastan I. Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: influence of interdomain connections. Proc Natl Acad Sci USA 1992; 89: 3075-3079.
45. Tang Y, Jiang N, Parakh C, Hilvert D. Selection of linkers for a catalytic single-chain antibody using phage display technology. J Biol Chem 1996; 271: 15682-15686.
46. Von Seggern DJ, Chiu CY, Fleck SK, Stewart PL, Nemerow GR. A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J Virol 1999; 73: 1601-1608.
47. Henning P, Lundgren E, Carlsson M, Frykholm K, Johannisson J, Magnusson MK et al. Adenovirus type 5 fiber knob domain has a critical role in fiber protein synthesis and encapsidation. J Gen Virol 2006; 87: 1351-1360.
48. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 2004; 12: 461-471.
49. Germershaus O, Merdan T, Bakowsky U, Behe M, Kissel T. Trastuzumabpolyethylenimine-polyethylene glycol conjugates for targeting HER2-expressing tumors. Bioconjug Chem 2006; 17: 1190-1199.
50. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991; 1: 72-82.
51. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002; 1591: 109-118.
52. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259: 7755-7760.
53. Lesley J, Schulte R, Woods J. Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp Cell Res 1989; 182: 215-233.
54. Nielsen UB, Marks JD. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharm Sci Technol Today 2000; 3: 282-291.
55. Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol 1994; 68: 5239-5246.